Composition: Granisetron HCl 1 mg Tablet
Granisetronbelongs to a group of medicines knownas ‘5-HT3 receptor antagonists’ or antiemetics or anti-sickness medicines. It works by blocking the action of a chemical messenger (serotonin) in the brain that may cause nausea and vomiting during anti-cancer treatment (chemotherapy) or after surgery,certain medicines, or stomach upset.It also prevents nausea due to motion sickness to some extent.
Granisetron tablets are indicated in adults for the prevention and treatment of acute nausea and vomiting associated with chemotherapy and radiotherapy.
Granisetron tablets are indicated in adults for prevention of delayed nausea and vomiting associated with chemotherapy and radiotherapy.
Talk to your doctor, nurse or pharmacist before usingthese tablets, especially if you:
- have a blockage in the intestine (gut) causingsymptoms such as stomach ache, wind, feeling orbeing sick, or difficulty passing stools.
- have heart problems, are being treated for cancerwith a medicine that is known to damage yourheart or have problems with levels of salts, suchas potassium, sodium or calcium, in your body(electrolyte abnormalities)
- are taking other ‘5-HT3 receptor antagonist’medicines. These include dolasetron, ondansetronused like granisetron in the treatment andprevention of nausea and vomiting.
Very common: may affect more than 1 in 10 people
- Your doctor will monitor your condition.
Common: may affect up to 1 to 10 people
- Problems sleeping (insomnia)
- Changes in how your liver is working shown byblood tests
Uncommon: may affect up to 1 in 100 people
- Skin rashes or an allergic skin reaction or “nettle-rash”or “hives” (urticaria). The signs may include red, raiseditchy bumps
- Changes in the heartbeat (rhythm) and changes seenon ECG readings (electrical recordings of the heart)
- Abnormal involuntary movements, such as shaking,muscle rigidity and muscle contractions.
Granisetron is a selective inhibitor of type 3 serotonergic (5-HT3) receptors. Granisetron has little or no affinity for other serotonin receptors, including 5-HT 1 , 5-HT 1A , 5-HT 1B/C , or 5-HT 2 ; for alpha 1 -, alpha 2 -, or beta-adrenoreceptors; for dopamine D 2 receptors; for histamine H 1 receptors; for benzodiazepine receptors; for picrotoxin receptors; or for opioid receptors. In most human studies, granisetron has had little effect on blood pressure, heart rate, or electrocardiogram (ECG). The drug is structurally and pharmacologically related to ondansetron, another selective inhibitor of 5-HT3 receptors. The serontonin 5-HT3 receptors are located on the nerve terminals of the vagus in the periphery, and centrally in the chemoreceptor trigger zone of the area postrema. The temporal relationship between the emetogenic action of emetogenic drugs and the release of serotonin, as well as the efficacy of antiemetic agents suggest that chemotherapeutic agents release serotonin from the enterochromaffin cells of the small intestine by causing degenerative changes in the GI tract. The serotonin then stimulates the vagal and splanchnic nerve receptors that project to the medullary vomiting center, as well as the 5-HT3 receptors in the area postrema, thus initiating the vomiting reflex, causing nausea and vomiting.
Mechanism of Action
Granisetron is a potent, selective antagonist of 5-HT3 receptors. The antiemetic activity of the drug is brought about through the inhibition of 5-HT3 receptors present both centrally (medullary chemoreceptor zone) and peripherally (GI tract). This inhibition of 5-HT3 receptors in turn inhibits the visceral afferent stimulation of the vomiting center, likely indirectly at the level of the area postrema, as well as through direct inhibition of serotonin activity within the area postrema and the chemoreceptor trigger zone.
Keep this medicine out of the sight and reach of children.Do not use Granisetron after the expiry date which is stated on the carton or label after EXP. The expiry daterefers to the last day of that month.